Literature DB >> 23882126

Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens.

Yan Jiang1, Ping Gong, Zeynep Madak-Erdogan, Teresa Martin, Muthu Jeyakumar, Kathryn Carlson, Ikhlas Khan, Troy J Smillie, Amar G Chittiboyina, Sateesh C K Rotte, William G Helferich, John A Katzenellenbogen, Benita S Katzenellenbogen.   

Abstract

Because little is known about the actions of botanical estrogens (BEs), widely consumed by menopausal women, we investigated the mechanistic and cellular activities of some major BEs. We examined the interactions of genistein, daidzein, equol, and liquiritigenin with estrogen receptors ERα and ERβ, with key coregulators (SRC3 and RIP140) and chromatin binding sites, and the regulation of gene expression and proliferation in MCF-7 breast cancer cells containing ERα and/or ERβ. Unlike the endogenous estrogen, estradiol (E2), BEs preferentially bind to ERβ, but their ERβ-potency selectivity in gene stimulation (340- to 830-fold vs. E2) is enhanced at several levels (coregulator recruitment, chromatin binding); nevertheless, at high (0.1 or 1 μM) concentrations, BEs also fully activate ERα. Because ERα drives breast cancer cell proliferation and ERβ dampens this, the relative levels of these two ERs in target cells and the BE dose greatly affect gene expression and proliferative response and will be crucial determinants of the potential benefits vs. risks of BEs. Our findings reveal key and novel mechanistic differences in the estrogenic activities of BEs vs. E2, with BEs displaying patterns of activity distinctly different from those seen with E2 and provide valuable information to inform future studies.

Entities:  

Keywords:  breast cancer cells; chromatin binding; gene regulation; proliferation

Mesh:

Substances:

Year:  2013        PMID: 23882126      PMCID: PMC3804744          DOI: 10.1096/fj.13-234617

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  60 in total

1.  Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods.

Authors:  Julia M W Wong; Cyril W C Kendall; Augustine Marchie; Zhen Liu; Ed Vidgen; Candice Holmes; Chung-Ja Jackson; Robert G Josse; Paul B Pencharz; A Venketeshwer Rao; Vladimir Vuksan; William Singer; David J A Jenkins
Journal:  Am J Clin Nutr       Date:  2012-02-01       Impact factor: 7.045

2.  Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.

Authors:  Tze Howe Charn; Edison Tak-Bun Liu; Edmund C Chang; Yew Kok Lee; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-06

3.  Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities.

Authors:  M Jeyakumar; Kathryn E Carlson; Jillian R Gunther; John A Katzenellenbogen
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

Review 4.  Development of subtype-selective oestrogen receptor-based therapeutics.

Authors:  Stefan Nilsson; Konrad F Koehler; Jan-Åke Gustafsson
Journal:  Nat Rev Drug Discov       Date:  2011-09-16       Impact factor: 84.694

5.  An ADIOL-ERβ-CtBP transrepression pathway negatively regulates microglia-mediated inflammation.

Authors:  Kaoru Saijo; Jana G Collier; Andrew C Li; John A Katzenellenbogen; Christopher K Glass
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

Review 6.  Alternative and complementary therapies for the menopause.

Authors:  Joan Pitkin
Journal:  Menopause Int       Date:  2012-03

7.  Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial.

Authors:  Silvina Levis; Nancy Strickman-Stein; Parvin Ganjei-Azar; Ping Xu; Daniel R Doerge; Jeffrey Krischer
Journal:  Arch Intern Med       Date:  2011-08-08

Review 8.  Is soy consumption good or bad for the breast?

Authors:  Leena Hilakivi-Clarke; Juan E Andrade; William Helferich
Journal:  J Nutr       Date:  2010-10-27       Impact factor: 4.798

9.  Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.

Authors:  A Bergamaschi; B S Katzenellenbogen
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

10.  Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists.

Authors:  Sreenivasan Paruthiyil; Aleksandra Cvoro; Xiaoyue Zhao; Zhijin Wu; Yunxia Sui; Richard E Staub; Scott Baggett; Candice B Herber; Chandi Griffin; Mary Tagliaferri; Heather A Harris; Isaac Cohen; Leonard F Bjeldanes; Terence P Speed; Fred Schaufele; Dale C Leitman
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

View more
  40 in total

1.  The effects of the botanical estrogen, isoliquiritigenin on delayed spatial alternation.

Authors:  Payel Kundu; Steven L Neese; Suren Bandara; Supida Monaikul; William G Helferich; Daniel R Doerge; Ikhlas A Khan; Susan L Schantz
Journal:  Neurotoxicol Teratol       Date:  2018-02-03       Impact factor: 3.763

2.  8-Prenylgenistein, a prenylated genistein derivative, exerted tissue selective osteoprotective effects in ovariectomized mice.

Authors:  Yan Zhang; Li-Ping Zhou; Xiao-Li Li; Yong-Jian Zhao; Ming-Xian Ho; Zuo-Cheng Qiu; Dong-Feng Zhao; Daniel Kam-Wah Mok; Qi Shi; Yong-Jun Wang; Man-Sau Wong
Journal:  Oncotarget       Date:  2018-03-19

3.  Ancestral resurrection of anthropoid estrogen receptor β demonstrates functional consequences of positive selection.

Authors:  Amy Weckle; Michael R McGowen; Jun Xing; Caoyi Chen; Kirstin N Sterner; Zhuo-Cheng Hou; Roberto Romero; Derek E Wildman
Journal:  Mol Phylogenet Evol       Date:  2017-09-13       Impact factor: 4.286

4.  Oxyresveratrol Is a Phytoestrogen Exerting Anti-inflammatory Effects Through NF-κB and Estrogen Receptor Signaling.

Authors:  Jing Wei; Jing-Rui Chen; Eva Maria Arriero Pais; Tai-Yi Wang; Lin Miao; Lan Li; Ling-Yan Li; Feng Qiu; Li-Min Hu; Xiu-Mei Gao; Guan-Wei Fan
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

Review 5.  Therapeutic perspectives of epigenetically active nutrients.

Authors:  M Remely; L Lovrecic; A L de la Garza; L Migliore; B Peterlin; F I Milagro; A J Martinez; A G Haslberger
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

Authors:  Jian Min; Valeria Sanabria Guillen; Abhishek Sharma; Yuechao Zhao; Yvonne Ziegler; Ping Gong; Christopher G Mayne; Sathish Srinivasan; Sung Hoon Kim; Kathryn E Carlson; Kendall W Nettles; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2017-07-14       Impact factor: 7.446

Review 7.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

Review 8.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11

Review 9.  Botanicals and Their Bioactive Phytochemicals for Women's Health.

Authors:  Birgit M Dietz; Atieh Hajirahimkhan; Tareisha L Dunlap; Judy L Bolton
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

10.  Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein.

Authors:  Columba de la Parra; Linette Castillo-Pichardo; Ailed Cruz-Collazo; Luis Cubano; Roxana Redis; George A Calin; Suranganie Dharmawardhane
Journal:  Nutr Cancer       Date:  2016-01-15       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.